Received Aug 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 3 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 4 | UNK | — |
suspected vaccination failure; shingles after 1st original shot; shingles after 2nd original shot; shingles after 1st newer shot; shingles after 2nd newer shot; received 1st newest shot; received 2nd newest shot; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis, Herpes zoster (Shingles vaccine) for prophylaxis and Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingles vaccine, the 2nd dose of Shingles vaccine, the 3rd dose of Shingles vaccine and the 4th dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, Shingles vaccine, Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: shingles after 1st original shot), shingles (Verbatim: shingles after 2nd original shot), shingles (Verbatim: shingles after 1st newer shot), shingles (Verbatim: shingles after 2nd newer shot), extra dose administered (Verbatim: received 1st newest shot) and extra dose administered (Verbatim: received 2nd newest shot). The outcome of the vaccination failure was not reported and the outcome of the shingles, shingles, shingles and shingles were resolved and the outcome of the extra dose administered and extra dose administered were not applicable. It was unknown if the reporter considered the vaccination failure, shingles, shingles, shingles and shingles to be related to Shingles vaccine. It was unknown if the reporter considered the vaccination failure, shingles, shingles and shingles to be related to Shingles vaccine. It was unknown if the reporter considered the vaccination failure, shingles and shingles to be related to Shingles vaccine. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine, Shingles vaccine, Shingles vaccine and Shingles vaccine. It was unknown if the company considered the shingles, shingles, shingles and shingles to be related to Shingles vaccine. It was unknown if the company considered the shingles, shingles and shingles to be related to Shingles vaccine. It was unknown if the company considered the shingles and shingles to be related to Shingles vaccine. It was unknown if the company considered the shingles to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 10-AUG-2025 This case was reported by the patient via interactive digital media. The patient had both the original shot and the newer 2 shot course, which led to an extra dose administered. The patient got shingles after each but only the mildest, most confined cases and gone quickly. The patient said that vaccines worked just fine. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, time to onset and laboratory confirmation of disease) is considered unrelated to GSK Shingles vaccine (Dose 1, 2, 3 & 4).